Timothy J. Ley, MD, a leukemia researcher and hematologist at the School of Medicine, has received a seven-year, $6.4 million Outstanding Investigator Award from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The funding will allow him to continue research aimed at understanding the mutations that initiate acute myeloid leukemia (AML), and how they might be targeted with new approaches.
Three scientists at Washington University School of Medicine in St. Louis and Siteman Cancer Center each will receive $900,000 in funding – $2.7 million total – over two years for their innovative approaches to fighting leukemia and other types of cancer.
Robert Schreiber, PhD, the Alumni Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis, has been named a co-editor-in-chief of Cancer Immunology Research.
Teresa Deshields, PhD, manager of Siteman Counseling Service at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, has been chosen as a 2015 fellow by the American Psychosocial Oncology Society.
Siteman Cancer Center plans to expand cancer services and facilities at Barnes-Jewish St. Peters Hospital in St. Charles County. The $13.1 million project will expand the existing facility from 19,500 square feet to 30,750 square feet. That is in addition to expansion projects already underway at Siteman’s main campus at Washington University Medical Center and at Siteman Cancer Center-South County.
The National Cancer Institute (NCI) has awarded Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis an “exceptional” rating, based on a rigorous review of Siteman’s research programs. The rating is the highest possible by the NCI, the principal federal institute that funds cancer research.
President Barack Obama has named internationally recognized cancer expert Timothy Ley, MD, of Washington University School of Medicine in St. Louis, to the National Cancer Advisory Board.
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The research is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer.
Siteman Cancer Center’s parent institutions have named two new leaders in radiation oncology. Dan Kinzel is executive director of radiation oncology at Washington University School of Medicine. Sharon Endicott is director of radiation oncology for Barnes-Jewish Hospital.
William Gillanders, MD, a physician-scientist and avid cyclist, keeps the wheels turning in the race against breast cancer. His career goal is to change treatment paradigms by making breast cancer vaccines a reality for those being treated for the disease.